Ten year follow‐up of high‐risk patients treated during the early experience with transcatheter aortic valve replacement

AbstractBackgroundThe long‐term clinical performance of transcatheter heart valves (THV) is unknown.AimsThis study assessed the clinical outcomes, rate of structural valve deterioration (SVD) and bioprosthetic valve failure in patients after transcatheter aortic valve replacement (TAVR) to 10‐year follow‐up.MethodsConsecutive patients undergoing TAVI for native aortic valve stenosis or failed aortic surgical bioprosthesis, between 2005 and 2009 at our institution were included. A total of 235 consecutive patients.ResultsAt the time of TAVI mean age was 82.4 ± 7.9 years. All patients were judged to be high risk, with a STS score > 8 in 53.6%. THVs implanted were the Cribier‐Edwards (20.9%), Edwards SAPIEN (77.4%) or CoreValve (1.7%). Mortality at 1, 5, and 10‐year follow‐up was 23.4%, 63%, and 91.6%, respectively. Of the total cohort, 15 patients had structural valve deterioration/bioprosthetic valve failure, with a cumulative incidence at 10‐years of 6.5% (95% CI 3.3%, 9.6%). The rate of SVD/BVF at 4, 6, 8, and 10 years was 0.4%, 1.7%, 4.7%, and 6.5%, respectively. Nine patients had moderate SVD and six patients had severe SVD. Of the six patients with severe SVD, two patients had reintervention (one patient had redo TAVR, and the second had surgical aortic valve replacement). Survivors (n = 19) at 10‐year follow‐up, had a mean gradient of 14.0 ± 7.6 mmHg and aortic regurgitation ≥moderate in 5%. Quality of life measures in 10‐year survivors demonstrated ADLs 6/6 in 43.8%, and ambulation without a mobility aid of 62.5%.ConclusionUsing early generation balloon expandable THVs in a high‐risk population, there was a low rate of structural valve deterioration and valve failure at 10‐year follow‐up. This study provides insights into the long‐term performance of transcatheter heart valves and patients self‐reported derived benefits.